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Abstract The study tests the hypothesis that in patients
admitted with acutely decompensated heart failure
(ADHF), achievement of adequate body hydration status
with intensive medical therapy, modulated by combined
bioelectrical vectorial impedance analysis (BIVA) and
B-type natriuretic peptide (BNP) measurement, may con-
tribute to optimize the timing of patient’s discharge and to
improve clinical outcomes. Three hundred patients admit-
ted for ADHF underwent serial BIVA and BNP measure-
ment. Therapy was titrated to reach a BNP value of
\250 pg/ml, whenever possible. Patients were categorized
as early responders (rapid BNP fall below 250 pg/ml); late
responders (slow BNP fall below 250 pg/ml, after aggres-
sive therapy); and non-responders (BNP persistently
[250 pg/ml). Worsening of renal function (WRF) was
evaluated during hospitalization. Death and rehospitaliza-
tion were monitored with a 6-month follow-up. BNP value
on discharge of B250 pg/ml led to a 25% event rate within
6 months (Group A: 17.4%; Group B: 21%, Chi2; n.s.),
whereas a value [250 pg/ml (Group C) was associated
with a far higher percentage (37%). At discharge, body
hydration was 73.8 ± 3.2% in the total population and
73.2 ± 2.1, 73.5 ± 2.8, 74.1 ± 3.6% in the three groups,
respectively. WRF was observed in 22.3% of the total.
WRF occurred in 22% in Group A, 32% in Group B, and
20% in Group C (P = n.s.). Our study conﬁrms the
hypothesis that combined BNP/BIVA sequential measure-
ments help to achieve adequate ﬂuid balance status in
patients with ADHF and can be used to drive a ‘‘tailored
therapy,’’ allowing clinicians to identify high-risk patients
and possibly to reduce the incidence of complications
secondary to ﬂuid management strategies.
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Introduction
Acute decompensated heart failure (ADHF) is characterized
by a combination of clinical, hemodynamic, and neurohor-
monal abnormalities [1]. Patient-oriented management
aiming at minimizing morbidity, hospitalizations, and
mortalityisachallengingbutimportanttarget[2].Patientsat
risk of events after hospitalization are often difﬁcult to
identify [3]; moreover, in spite of technological advances
and the search for objective, evidence-based criteria, dis-
charging a patient hospitalized for ADHF, is still largely
based on subjective feelings of the treating physician [4].
Recently, natriuretic peptide (NP) levels have emerged as
robust prognostic indicators in ADHF [5, 6]. NP levels
obtained at the time of hospital discharge predict clinical
outcomes following hospitalization for ADHF [6–8].
NP levels rapidly decrease after short-term therapeutic
strategies [9], and decreased levels correlate with a
reduction in ﬂuid overload and improvement of hydration
status [10, 11]. Nevertheless, targeting a speciﬁc reduction
in body weight is often difﬁcult because of the complexity
of determining accurate body ﬂuid status [12]. Further-
more, levels of BNP can remain high even after achieving
an adequate hydration status because of a stretched myo-
cardium (i.e., dry BNP), renal failure, liver failure, pul-
monary embolus, and acute coronary syndromes [6, 10].
Recently, bio-impedance vector analysis (BIVA) has
been suggested as a tool to assist in volume status assess-
ment in patients with heart failure. BIVA allows a rapid,
accurate, and non-invasive determination of body hydra-
tion status, correlates with NYHA class, and seems to
demonstrate high diagnostic accuracy for the differential
diagnosis of HF-induced dyspnea [14]. Moreover, type 1
cardiorenal syndrome (CRS) may often complicate the
course of ADHF where the use of loop diuretics typically
reduces congestion at the cost of renal hypoperfusion and
worsening of renal function (WRF) [15, 16]. Thus, by
providing an accurate index of total body ﬂuid, BIVA may
be used to guide ﬂuid-related therapies [10, 11, 13].
The technologies of BIVA and BNP may be applied in
combination and when used together may provide greater
accuracy for volume assessment in heart failure. In fact,
one study found that this combination provided better
diagnostic accuracy than either used alone [14]. Further-
more, we previously reported that BNP-guided treatment
and body hydration status monitoring helped to optimize
the patient’s discharge volume status as well as predict the
occurrence of cardiovascular events [17]. Thus, by using
both technologies simultaneously, BIVA and BNP may
represent a useful tool, providing accurate insights into
body volume status, and may be an aid to drive therapeutic
interventions in these patients. The hypothesis of this
present study is that in patients hospitalized with ADHF,
effective reduction in congestion with intensive medical
therapy guided by BIVA and BNP measurements may
contribute achieving optimal hydration status and therefore
help optimize discharge timing and decrease long-term
complications. A second end point was also prespeciﬁed to
determine whether optimization of dry weight by BIVA
contributes to reduction in the development of WRF.
Methods
Population
Subjects (age C18 years) admitted to the heart failure unit
(HFU) of two large community hospitals with a primary
diagnosis of ADHF were consecutively enrolled over a
period of 24 months. Eligibility criteria included the fol-
lowing: (1) symptoms of HF [18]; (2) NYHA functional
classes III or IV, with an acute exacerbation of symptoms
of at least 1 class (ADHF); (3) evidence of systolic and/or
diastolic dysfunction by echocardiography; (4) BNP
C250 pg/ml, in the absence of end-stage renal failure or
acute coronary syndromes. The value of 250 pg/ml was
selected to increase speciﬁcity [17, 19]. Institutional review
boards of participating centers approved this project.
Informed consent was obtained for hospitalization and
treatment and was documented in the medical records.
Data were collected per medical chart review.
Clinical monitoring and medical therapy
during hospitalization
All patients were treated at the direction of the treating
physician per international ADHF guidelines [20]. BNP,
serum creatinine, and blood urea nitrogen values were
recorded on admission and at least every other day
throughout hospitalization, including the day of discharge.
BIVA measurement was taken at admission, on the day of
restoration of clinical stability, and at discharge. Restora-
tion of clinical stability was deﬁned by 6 criteria [17],
including the following: (a) subjective improvement on the
basis of NYHA class (improvement of orthopnoea in
refractory NYHA class IV); (b) systolic blood pressure
between 90 and 120 mmHg; (c) heart rate \100 bpm;
(d) pulse oxymetry in ambient air [90%; (e) diuresis
[1,000 ml/24 h; (f) improvement in ﬂuid overload
(migration trend of the BIVA value toward normal in the
relevant nomogram).
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to document the achieved ‘‘clinical stability’’ and to drive
discharge, per our previously published protocol [17].
Patients with a BNP value[250 pg/ml were given one or
more of the following measures: (a) ‘‘prolonged’’ i.v
diuretic treatment (up to 500 mg/day of furosemide) unless
a status of dehydration was documented by BIVA or serum
creatinine increased[0.3 mg/dl was observed; (b) scaling
up of the ACE inhibitor dose (up to enalapril equivalent of
20 mg/12 h); (c) strict blood pressure monitoring (target
systolic value \100 mmHg); and heart rate control
(\80 bpm); d) oral/i.v. vasodilators.
Responses to treatment classiﬁcation
For the analysis, patients were stratiﬁed into three groups
based on BNP changes in response to therapy. These
included early-, late-, and persistent categories.
Early responders: This group consisted of patients with
initially high BNP levels that tended to drop rapidly after
early pharmacological management and represents patients
who often could be discharged early with a low rate of
complications in the follow-up period [17].
Late responders: This cohort represents patients with
limited initial response to medical therapy but, who sub-
sequently, after a more aggressive treatment, demonstrated
a late reduction in BNP and decreased in congestion. These
patients can be discharged later with a slightly higher
long-term complication rate as compared with the early
responders [17].
Non-responders: These subsets are those patients who
never achieve a signiﬁcant reduction in BNP level despite
aggressive therapy. Although having nearly normal ﬂuid
status, these patients have high BNP levels (Dry BNP) and
display a very narrow window of adequate hydration,
easily falling into conditions of hyper- or hypovolemia.
These patients have a signiﬁcantly worse prognosis than
either early- or late responder groups [17].
Cardiorenal interactions and kidney function
measurement
We deﬁned WRF as an increase in serum creatinine of
C0.3 mg/dl during hospitalization, consistent with several
previous investigations [21–23] and the most recent classi-
ﬁcation of acute kidney injury [24, 25]. Estimated glomer-
ular ﬁltration rate (eGFR) was calculated using the
simpliﬁedmodiﬁcationofdietinrenaldiseaseequation[26].
BNP assay
Whole blood samples were immediately analyzed by the
immunoﬂuorescent BNP Triage point of care (Alere, San
Diego, CA, USA) platform. The method requires a mini-
mum sample volume of 250 ll and has a detection limit of
10 pg/ml.
Doppler echocardiography
Echocardiography examinations were carried out on
admission, blinded to the BNP value. Left ventricular
systolic dysfunction was deﬁned as an ejection fraction
(EF) \50%. The left ventricular EF was measured using
Simpson’s biplane method. Diastolic function was deﬁned
per classiﬁcations used in prior studies [17, 27].
Bioelectrical impedance vectorial analysis
Assessment of body ﬂuid status was made with an electrical
impedance analyser and Cardio EFG software (Akern,
Pontassieve, Florence, Italy). The bioelectrical parameters
of resistance, reactance, and phase angle were determined
using an electric alternating current ﬂux of 800 microA and
an operating frequency of 50 kHz. Whole-body impedance
measurements were taken by using a standard position of
outer and inner electrodes on the right hand and foot. The
entire procedure was performed per the National Institutes
of Health technology assessment conference statements
[28]. For each patient, a database was created including
anthropometric data (height, weight, and body mass index).
Bioelectrical impedance vector analysis simultaneously
evaluates total body by resistance and reactance (reactance
is a form of opposition that electronic components exhibit to
the passage of alternating current because of capacitance or
inductance; in some respects, reactance is like an alternating
current counterpart of direct current and indicates an abso-
lute amount of body cell mass), presenting them graphically
to provide indices of total body hydration status. BIVA can
also provide data regarding the ratio of extracellular water
and total body water.
BIVA data can be visually presented as a nomogram
classifying patients into 3 classes as follows: normally
hydrated, hyperhydrated, or dehydrated. The latter classes
can be further subdivided into mild, moderate, or severe
volume abnormalities [29, 30]. Using BIVA [31] (Fig. 1), a
forward or backward displacement of vectors parallel to the
major axis of the standard deviation ellipses is associated
with dehydration or ﬂuid overloading, respectively, reach-
ing extremes out of the poles (left panel Fig. 1). Vectors
above orbelow theminoraxis(meaningupper-leftorlower-
right half of ellipses) are associated with more or less cell
mass in soft tissues, respectively, with extremes along the
minor axis. The need of a numerical value has led to the
construction of a numerical scale (right panel in Fig. 1)i n
which the normal level of hydration is set at 73.3%. Values
above or below represent, respectively, dehydration or
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BIVA nomogram. The migration of the vector in the
nomogram results in variations of the numerical value of the
hydration status (example A to B in Fig. 1).
Follow-up
Before discharge, all patients underwent medical and nurse
visitforevaluationandcomprehensiveeducationofthepatient
and family. Eligible patients were then discharged with
guideline compliant pharmacologic therapy, a thorough pre-
scription of diet and behavioral recommendations at home.
Clinic visits were scheduled at 2, 6, 12, 24, and 36 weeks.
Clinical end points
Primary clinical end points were death and/or hospital
readmissions for ADHF during the 6 months after dis-
charge. Other end points included discharge hydration
status (with measures of BIVA and BNP), determination of
‘‘dry’’ BNP levels, and if AKI occurred at any time during
hospitalization.
Statistical analysis
Categorical data are presented as numbers (percent) and
continuous data as means ± standard deviation. Alpha was
deﬁned as P\0.05 was considered signiﬁcant. Mann–
Whitney U-test and Wilcoxon test were used for com-
parisons between samples, while associations between
variables were veriﬁed by Fisher’s exact test. One-way
ANOVA was also used. Cox proportional hazards regres-
sion models were used to examine the relation of clinical
variables, BNP levels, and echocardiographics parameters
with the incidence of the combined end point during the
6 months after discharge. A ROC (receiver-operated curve)
analysis was performed to show various cutoff values for
BNP and to identify patients likely to suffer an event in the
6 months after discharge. BNP levels were evaluated both
as a continuous variable and as a categorical variables
(based on cutoff values). To evaluate clinical events in
relation to BNP levels, Kaplan–Meier curves are pre-
sented. Analyses were performed using SPSS software per
Windows, release 11.0, SPSS Inc., Chicago, USA).
Results
Patient parameters
Three hundred patients were enrolled in the study over
24 months. Table 1 summarizes their characteristics and
the evolution of several parameters throughout hospital-
ization and follow-up. Overall, most patients were elderly
Fig. 1 Graphic representation of the nomogram (left panel) and the
numerical scale (right panel) for BIVA. A typical example of vector
migration (A to B) in response to aggressive ﬂuid depletion therapy is
reported. Corresponding values are reported in the numerical scale.
Impedance (Z vector) is a combination of Resistance (R) and
Reactance (Xc) across ionic solutions of soft tissues, tissue interfaces
and cell membranes. Impedance at 50 kHz is represented with a
complex number (a point) in the real-imaginary plane (Z vector), that
is a combination of R (i.e. the opposition to ﬂow of an alternating
current through intra- and extra cellular ionic solutions, representing
the real part of Z) and Xc (i.e. the capacitative component of tissue
interfaces, and cell membranes and organelles, representing the
imaginary part of Z). The volume of intra and extra cellular ionic
solutions is (inversely) related to the R component of Z. The amount
of soft tissue structures containing the solutions is (directly) related to
the Xc component of Z. The arc tangent (Xc/R) is called the phase
angle (Xc on the ordinate and R on the abscissa axis)
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123(average age 77 ± 10 years), equally distributed for sex,
with a high ischemic heart disease (39%). The ratio of iso-
lateddiastolicdysfunction (EF[50%)accountedfor38%of
thetotalpopulation,and24%hadarestrictivemitralpattern.
The average length of stay was 6.3 ± 4.1 days.
BNP and clinical response data
BNP in the whole population was elevated, with a marked
reduction from admission to discharge (1,017 ± 968 to
665 ± 803 pg/ml; Wilcoxon test, Z =- 8.5; P\0.001).
Of the total 300 patients, 46 (15.3%) achieved restoration
of clinical stability with a BNP \250 pg/ml within 72 h
(early responders) and were discharged (Fig. 2). The
remaining 254 patients underwent ‘‘aggressive treatment.’’
Among this cohort, 56 patients (18.7%) were discharged
several days later with a BNP value \250 pg/ml (Late
responders). The remaining 198 patients (66%) were dis-
charged with a BNP value [250 pg/ml in spite of a pro-
longed aggressive therapy (non-responders). Length of stay
Table 1 Clinical characteristics of the 300 patients studied, according to BNP changes
Parameters All patients
(n = 300)
Early responders
Group A, n = 46
Late responders
Group B, n = 56
Non-responders
Group C, n = 198
Age (years) 77 ± 10 76 ± 97 8 ± 10 77 ± 11
Male (%) 55 50 45 59
Ischemic etiology (%) 39* 22 34 44
Echocardiographic parameters
Left ventricular ejection fraction (%) 46 ± 17 54 ± 12 56 ± 14 44 ± 15a,b
Preserved left ventricular (C50%) (%) 45** 65 69 33
Diastolic restrictive pattern (%) 22 22 14 24
Laboratory parameters
BNP on admission (pg/ml) 1,017 ± 968 406 ± 202 569 ± 499 1,285 ± 1061a,b
BNP on clinical stability (pg/ml) 844 ± 885 151 ± 74 344 ± 392 1,114 ± 950a,b
BNP on discharge (pg/ml) 665 ± 803 145 ± 67 143 ± 60 933 ± 874a,b
Creatinine on admission (mg/dl) 1.66 ± 1.21 1.18 ± 0.33 1.70 ± 1.40 1.76 ± 1.27a
Creatinine on discharge (mg/dl) 1.72 ± 1.31 1.28 ± 0.42 1.87 ± 1.59 1.78 ± 1.31
eGFR on admission (ml/min/m
2)5 0 ± 22 60 ± 20 48 ± 21a 48 ± 21a
eGFR on discharge (ml/min/m
2)4 9 ± 22 57 ± 22 47 ± 23 47 ± 21a
Worsening renal function (%) 22 22 32 20
Transient AKI (%) 2.0 0 1.8 2.5
Creatinine C2.5 mg/dl) on admission 13** 0 9 17
Creatinine C2.5 mg/dl) on discharge 13* 0 14 16
Body hydration on admission (%) 76.4 ± 4.5 75.1 ± 3.6 76.5 ± 5.1 76.7 ± 4.9
Body hydration on clinical stability (%) 74.2 ± 0.3 73.3 ± 0.1 74.0 ± 0.4 74.5 ± 0.4
Body hydration on discharge (%) 73.8 ± 3.2 73.2 ± 2.1 73.5 ± 2.8 74.1 ± 3.6
Distribution of body hydration on discharge
Moderate o severe dehydration (%) 5.7 4.3 7.1 5.6
Mild dehydration (%) 7.6 4.3 3.6 7.6
Normal hydration (%) 76.3 87.0 82.1 72.2
Mild hyperhydration (%) 7.3 4.3 3.6 9.1
Moderate/severe hyperhydration (%) 5.6 0 3.6 5.6
Length of stay (days) 6.3 ± 4.1 3.0 ± 0.9 8.0 ± 3.5a 6.6 ± 4.2a,b
6-month event-free survival (%) 69.0** 82.6 78.6 63.1
6-month death (%) 6.0 2.2 5.3 7.1
6-month readmission for heart failure (%) 25.0** 15.2 16.1 29.8
The values are expressed as mean ± SD, unless otherwise speciﬁed. * and ** P\0.05 and P\0.01 Chi2 test. a and b = P\0.05, ONE-WAY
ANOVA and Tukey’s test, respect to ‘‘early-’’ and ‘‘non-responders’’ respectively. Severe dehydration (\69.0%); moderate dehydration
(69.1–71.0%); mild dehydration (71.1–72.70%); normohydration (72.71–74.30%); mild hyperhydration (74.31–81.0%); moderate hyperhydra-
tion (81.1–87.0%); severe hyperhydration (C87.1%)
BNP B-type natriuretic peptide, eGFR estimated glomerular ﬁltration rate
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123was signiﬁcantly shorter in early responders than in either
the late- or non-responders groups: 3.0 ± 0.9 days in early
responders vs. 8.0 ± 3.5 and 6.6 ± 4.2 days for late
and non-responders, respectively (one-way ANOVA and
Tukey’s test, P\0.05) (Table 1 and Fig. 3).
BNP levels at discharge were similar in the early- and
late responders (145 ± 67 and 143 ± 60 pg/ml, respec-
tively) and signiﬁcantly lower than those observed in the
non-responders (933 ± 873 pg/ml; one-way ANOVA and
Tukey’s test, P\0.05). (Figure 3). The decrease in dis-
charge BNP levels compared with that of the admission
levels was larger in both early- and late responders than in
the remaining patients: -61 ± 20% and -66 ± 20%
versus -4 ± 84% (one-way ANOVA and Tukey’s test,
P\0.05). The most signiﬁcant reduction in BNP levels in
late responders (P\0.001) was obtained after clinical
stabilization (admission: 570 ± 498 pg/ml, clinical stabil-
ity: 398 ± 293 pg/ml, discharge: 142 ± 69 pg/ml).
Non-responders had higher frequency of ischemic eti-
ology and worse LVEF than patients in groups early- or
late responders. Early responders showed lower creatinine
levels at all time points (Table 1). Additionally, higher
doses of furosemide were prescribed to the late- and non-
responders (89 ± 145 and 99 ? 165 mg/day) than to early
responder group (30 ± 29 mg/day; P\0.05).
Body hydration status
For purposes, of this study, we selected the percentage
hydration scale values to characterize patients at admission
and at discharge (Fig. 1). At admission, the overall popu-
lation presented an average value of body hydration of
76.4 ± 4.5%, conﬁrming a trend toward ﬂuid overload.
Although hyperhydration was the prevalent feature of our
cohort, the accurate assessment of body hydration by BIVA
demonstrated that a wide distribution of ﬂuid balance dis-
orders is present in our population (Table 1, Fig. 4). The
average values did not differ signiﬁcantly in the three
groups (75.1 ± 3.6, 76.5 ± 5.1, 76.7 ± 4.9%, P = n.s.),
and therefore, a case-by-case analysis was carried out to
drive therapy during and after admission.
At discharge, body hydration was 73.8 ± 0.03% in the
totalpopulationand73.2,73.5,and74.1%intheearly-,late-
, and non-responder groups, respectively; 76.3% of patients
were classiﬁed as normohydrated, while 6.3 and 5.7%
demonstrated mild or moderate–severe dehydration, and 7.3
and 4.3% mild or moderate–severe hyperhydration,
respectively (Table 1; Fig. 4). Normohydration at discharge
was achieved in 72% of non-responders (after 2.0 ±
3.4 days), 82% of late responders (after 1.9 ± 2.4 days),
and 87% of early responders (after 1.0 ± 1.2 days) (Chi2
5.8; P = 0.05). Patients free from hyperhydration at dis-
charge (i.e., normohydrated plus dehydrated) were 96, 93,
and85%ofearly-,late-,andnon-responders(Chi25.2;n.s.).
It should be noted, however, that at discharge, the distribu-
tionofhydrationstatusinthepopulationpresentsanarrower
bell-shaped curve indicating a trend toward normalization
(Fig. 4, right panel).
Cardiorenal interactions and kidney function
parameters
Overall mean admission creatinine was 1.7 ± 1.2 mg/dl. It
was lower in early responders (1.2 ± 0.3 mg/dl) in com-
parison with late- and non-responders: 1.7 ± 1.4 and
1.8 ± 1.3 mg/dl (one-way ANOVA and Tukey’s test,
P\0.05), respectively. Discharge creatinine showed a
similar pattern, being 1.7 ± 1.2 mg/dl in the overall
Fig. 2 Flow-chart of patient’s outcome based on BNP values and
BIVA measurements
Fig. 3 BNP levels (pg/ml) on admission, clinical stability, and
discharge. Length of stay was 3.0, 8.1 and 6.6 days in the three groups
respectively. * P\0.05; Oneway Anova ? Tukey’s Test
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123population and 1.3 ± 0.4, 1.9 ± 1.6 and 1.8 ± 1.3 mg/dl
in the early-, late-, and non-responder groups, respectively
(one-way ANOVA and Tukey’s test; P\0.05). Creatinine
levels at discharge were[2.5 mg/dl in 13% of all patients
and in 0, 14.3, and 16.2%, of early-, late-, and non-
responders in comparison with 0, 8.9, and 16.7% at
admission, respectively.
At discharge, eGFR was 49 ± 22 ml/min/m
2 (57 ± 22,
47 ± 21, and 49 ± 22 ml/min/m
2 in the early-, late-, and
non-responders, respectively; one-way ANOVA and
Tukey’s test, P\0.05), being unchanged with respect to
admissionvalues:50 ± 22 ml/min/m
2overalland60 ± 20,
48 ± 21, and 48 ± 21 ml/min/m
2 (one-way ANOVA and
Tukey’s test, P = n.s.), in the early-, late-, and non-
responder groups. Considering the overall population, WRF
was observed in 67 patients (22.3% of the total). WRF
occurred in 22, 32, and 20% of the early-, late-, and non-
responder groups, while a transient WRF was seen in 0, 2,
and 3% of patients, respectively (P = n.s.) (Table 1). These
data suggestthat a signiﬁcantnumberof hospitalized ADHF
patients presents with a wide spectrum of kidney dysfunc-
tions already present at admission. This may result from a
cardiorenal syndrome type 2 or from a preexisting general
condition of chronic kidney disease (CKD). However, in
comparison with previously reported data of AKI occurring
in 34% [21] and 37% [32] of hospitalized ADHF patients,
BIVA/BNP-driventherapyseemstolimittheoccurrencesof
WRF (Table 1). This may be due to a more appropriate
management of the ﬂuid balance and hydration status, but
will require validation in randomized studies.
BNP, body hydration status, and clinical events
during the follow-up period
BNP levels at discharge were signiﬁcantly lower in
the event-free patients than in the patients who had suffered
at least one event: 780 ± 734 pg/ml versus 1,156 ±
1,052 pg/ml Mann–Whitney U-test, Z =- 3.0, P = 0.003,
and 468 ± 606 versus 751 ± 808 pg/ml, Mann–Whitney
U-test Z =- 3–7, P = 0.000).
Patients with BNP\250 pg/ml at discharge (early- and
late responders) showed less cumulative events (20%) in
comparison with non-responders (36%) (P = 0.003). No
signiﬁcant differences in event rate were seen in relation to
the time necessary to obtain a reduction in BNP values
below 250 pg/ml (18 vs. 21% for early—vs. late
responders, respectively, P = 0.31) (Fig. 5).
Discussion
In the present study, patients hospitalized for ADHF pre-
sented with various degrees of congestion, and all
Fig. 5 Kaplan–Meier curves showing the cumulative incidence of
death and readmission in early- and late-responders and non-
responders (see text)
Fig. 4 Distribution of body hydration status on admission and
discharge. A: severe de-hydration (\69.0%); B: moderate de-hydra-
tion (69.1–71.0%); C: mild de-hydration (71.1–72.70%); D: normo-
hydration (72.71–74.30%); E: mild hyper-hydration (74.31–81.0%);
F: moderate hyper-hydration (81.1–87.0%); G: severe hyper-hydra-
tion (C87.1%)
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123displayed high BNP levels. Despite a reduction in con-
gestion in all groups, changes of BNP in response to
therapy, described as early-, late-, and non-responders,
were subsequently associated with post-discharge out-
comes (Fig. 5). This, together with an accurate determi-
nation of the hydration status by BIVA, helped identifying
the true hydration status, also described as ‘‘dry’’ BNP in
patients with HF. We found the combination of BNP and
BIVA measurement, helped to avoid unnecessary aggres-
sive diuretic therapy, reducing the level of renal compli-
cations, especially in the early- and non-responder groups.
This was in distinction to the late responders group, who
received the more aggressive and prolonged diuretic ther-
apy in order to achieve BNP reduction, occurring at the
expense of a trend of more WRF and AKI. These results,
conﬁrm that the status of hydration and myocardial per-
formance in patients with HF, are linked by a complex
relationship. Analyzing case by case, it is possible to
establish that every patient has a ‘‘personal’’ threshold of
hyper- or hypohydration leading to congestion or organ
hypoperfusion and hemodynamic instability, respectively.
As reported elsewhere, the majority of patients admitted
with ADHF display a good response to loop diuretics and
vasoactive agents [35]; however, in some cases, subclinical
volume expansion may result in diuretic under-treatment
and progressive worsening of symptoms [33, 34]. On the
other hand, excessive diuretic therapy in patients with mild
overhydration may lead to dehydration and organ hypo-
perfusion. For this reason, an accurate assessment of body
ﬂuid status is essential in HF patients.
The effect of volume status on plasma BNP levels has
been examined previously in patients with HF [36]. In
chronic HF, clinically unrecognized hyperhydration is
frequently present in non-edematous patients with HF and
is associated with increasing ﬁlling pressures [37]. Since
BNP release is triggered by increased volume load and
myocadiac wall stretch [38], the level of BNP has been
proposed as a ‘‘surrogate’’ of congestion. It is hypothesized
that the BNP level of a patient admitted with ADHF is a
result of two components: a baseline, euvolemic ‘‘dry’’
BNP level (reﬂecting myocardial status), and a volume/
pressure-induced ‘‘wet’’ BNP (reﬂecting hydration status)
[6].
Guidelines to assess congestion during hospitalization or
pre-discharge are not well established. In ﬂuid overloaded
patients requiring diuresis, standard monitoring includes
the evaluation of clinical signs and symptoms, chest X-ray,
and body weight change. Although an increase in body
weight predicts hospitalization [39], its reduction in
response to therapy may not result in better outcomes.
Nevertheless, quantifying the extent of congestion and
body hydration status in these patients is difﬁcult. In
this setting, clinical and radiographic ﬁndings show poor
correlation with invasive measurements of pulmonary
capillary wedge pressures [40]. Other methods that directly
measure extravascular lung water are expensive, compli-
cated, and not widely available [13].
We found that the BNP/BIVA combination may add
useful information to standard clinical parameters in
guiding diuretic therapy and congestion relief strategies.
Our study demonstrates the complex link between body
ﬂuid status and BNP levels during hospitalization for
ADHF and the importance of ‘‘euvolemia’’ concept. At
stable BNP levels, some patients may have a very narrow
volume window, with small changes resulting in conges-
tion or organ hypoperfusion. In these patients, failure to
achieve an optivolemic state at discharge may result in
higher rates of short- and long-term complications. Fur-
thermore, inadequate diuretic use may cause AKI because
of renal arterial underﬁlling and inadequate renal response
to hormonal stimuli [41]. In this settings, BNP/BIVA-
guided management allows the differentiation of ‘‘wet’’
and ‘‘dry’’ BNP values, thus avoiding over- or under-
treatment of patients and preventing long-term complica-
tions and WRF.
Finally, despite aggressive therapy, some patients never
reach target levels of BNP (\250 pg/ml in our study),
despite of apparent euvolemia. These non-responders are
subject to higher rates of long-term complications, rehos-
pitalization, and death. When BIVA values describe a
nearly normal hydration status in these patients, BNP
represents the ‘‘dry’’ component of the neurohormonal
response to myocardial dysfunction.
The prognostic role of neurohumoral markers in ADHF
is of growing clinical importance. Natriuretic peptides are
currently the benchmark against which all new biomarkers
must be compared. However, growing evidence shows that
hypervolemia by itself is independently associated with
mortality and it can be considered a biomarker itself [38,
42, 43]. A recent review [1] states that discharge after
complete resolution of signs and symptoms compared with
earlier discharge with residual symptoms and close follow-
up for further optimization should be compared. This
concept has been supported in a contemporary consensus
paper [6] where the BNP/NT-proBNP pre-discharge level
is suggested as a tool to establish the patient’s ‘‘dry
weight.’’ We would like to further extend this concept and
introduce the use of BIVA as an additional measure to
support clinical decisions. In a previous study, we dem-
onstrated that the extent and rapidity of changes in the BNP
level during hospitalization (an average of 5.5 days) is a
reliable outcome predictor in ADHF [17]. The current
study extends these ﬁndings and demonstrates that BIVA/
BNP-guided management during hospitalization for HF is
associated with lower events after discharge, independently
of other prognostic variables. In the present study, the
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123threshold level 250 pg/ml was derived from an ROC
analysis and the calculated optimal cutoff was chosen to
divide patients according to BNP values on discharge.
Among patients with a ﬁnal concentration of 250 pg/ml,
subsequent events were signiﬁcantly lower in those who
reached a BIVA-guided level below this threshold at
discharge.
Most patients have rapid symptomatic improvement
with loop diuretics and have a relatively short hospital stay
[35]. We have characterized the response of patients with
ADHF into three groups: early responders, late responders,
and non-responders. In the ﬁrst two groups, where the only
difference was the time necessary to obtain a reduction in
BNP values below 250 pg/ml, no differences in event rates
were noticed (17.4 vs. 21% for ‘‘early responders’’ and
‘‘late –responders,’’ respectively, P = 0.31). On the con-
trary, the third group of patients that never reached BNP
\250 pg/ml at discharge displayed marked modiﬁcation of
the prognosis with high rate of complications, death, and
rehospitalization. In other words, patients with an initial
BNP concentration above the threshold level have, on
average, markedly divergent outcomes depending on
whether they maintain or reduce their level of BNP after
receiving a BIVA-guided treatment of ﬂuid overload. It
must be emphasized, however, that in all groups, mid-long-
term complications were markedly lower than those
reported in the literature [21, 22, 32], supporting the con-
cept that BIVA-guided therapy may signiﬁcantly contrib-
ute to achieve the best BNP level possible, minimizing and
limiting the negative effects of an inadequate and aggres-
sive diuretic or ﬂuid removal therapy.
Therefore, our data support a strategy of serial deter-
minations of BNP concentration during in-hospital phase
and classiﬁcation into categories of changes according to
threshold levels combined with and hydration status mea-
sured by BIVA. This approach appeared in our study is
adequate for risk stratiﬁcation of patients with ADHF.
Limitations
This study has several limitations, the most important of
which is there was no blinded randomized control arm to
determine what could be the concurrent effect of contem-
porary non-BIVA-guided therapy. Thus, a further pro-
spective study is warranted. Secondly, this single-center
study may not be generalizable to other populations, as
treatment strategies and the speciﬁc population enrolled,
may explain why the overall rate of adverse events was
lower than reported in other large trials. Finally, treatment
strategies were left to the attending physician. By not
having a standard treatment algorithm, duplication of our
results may be challenging.
With regard to the hydration status at discharge, because
we could not reach a net separation among the groups, it is
impossible to determine whether different classes of
hydration described by BIVA correlate with speciﬁc out-
comes. However, we speculate that the concept of adequate
hydration status may be different from case to case and
above all, the window of tolerance for hyper- or dehydra-
tion may be wider or tighter in patients affected by dif-
ferent heart disorders. Nevertheless, the low incidence of
WRF in the overall treated population and the low rate of
long-term complications observed in all groups suggests
that the combined BIVA/BNP measure as a driving diag-
nostic tool for ﬂuid removal therapy may represent a sig-
niﬁcant advance in the management of ADHF patients.
Conclusion
We found the addition of BIVA to serial BNP measure-
ment allowed a more accurate risk stratiﬁcation of patients
undergoing diuretic therapy potentially leading to a better
treatment strategy and reduction in complications. Thus,
the combination of BNP and BIVA measurements may
represent a novel, but logical criteria for discharge and risk
stratiﬁcation.
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